Clinical Trials Logo

Filter by:
NCT ID: NCT06105294 Terminated - Bipolar Disorder Clinical Trials

Time-Restricted Eating and Bipolar Disorder

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This is a pilot trial to examine the acceptability and feasibility of time-restricted eating as an adjunct to medication treatment for bipolar disorder.

NCT ID: NCT06105242 Recruiting - CTEPH Clinical Trials

Biological Sex and CTEPH-related RV Dysfunction and Recovery (BIOSPHeRe)

Start date: May 30, 2022
Phase:
Study type: Observational [Patient Registry]

1. To identify biological sex differences in baseline RV function in CTEPH 2. To identify biological sex differences in recovery of RV function after PTE surgery in CTEPH 3. To determine if sex hormone levels relate to RV function at CTEPH diagnosis and during recovery after PTE.

NCT ID: NCT06105164 Not yet recruiting - Obesity Clinical Trials

Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans

Start date: February 2024
Phase: N/A
Study type: Interventional

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study satiety in healthy individuals. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study, the investigators will be stimulating the brain to learn more about the role of the cerebellum in satiety.

NCT ID: NCT06105138 Completed - Clinical trials for Alcohol Use Disorder

Cannabidiol Effects on Blood Alcohol Level and Intoxication

Start date: March 9, 2021
Phase: N/A
Study type: Interventional

The main objectives of this study were to test if 2 different doses of Cannabidiol (compared to placebo) alter 1) breath alcohol concentration, 2) craving and subjective responses to alcohol or 3) cognitive performance following a standard dose of alcohol.

NCT ID: NCT06105021 Recruiting - Colorectal Cancer Clinical Trials

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Start date: March 6, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.

NCT ID: NCT06104969 Recruiting - Diabetes Clinical Trials

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

Start date: June 15, 2023
Phase:
Study type: Observational

This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions

NCT ID: NCT06104904 Recruiting - Anxiety Clinical Trials

Managing Anxiety in Pediatric Primary Care (MAPP)

MAPP
Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to conduct a randomized controlled trial to enhance the capacity of pediatric primary care providers to assist their patients who struggle with anxiety. The study aims to refine and assess the feasibility of the Anxiety Action Plan (AxAP), a brief intervention to reduce pediatric anxiety, delivered by primary care providers (PCPs) in community pediatric primary care clinics. The goal of the AxAP is to enhance the capacity of PCPs to identify and intervene with anxious youth, which will enhance access to care in general and especially in locations with few mental health specialists. PCPs participating in this study will attend a training, administer the intervention to enrolled youth assigned to the MAPP condition, participate in coaching sessions, and fill out study questionnaires. Families participating in this study will complete evaluations with the study team, receive the intervention from their PCP (if assigned to the MAPP condition), and fill out study questionnaires. Researchers will compare the MAPP intervention to Enhanced Usual Care (EUC; consisting of videos, handouts, and other resources for anxiety reduction) to see the differences, if any, in child outcomes.

NCT ID: NCT06104891 Completed - Fatigue Clinical Trials

Radicle Recharge: A Study of Health and Wellness Products on Energy Levels and Other Health Outcomes

Start date: October 25, 2023
Phase: N/A
Study type: Interventional

A randomized, double blind, placebo-controlled trial assessing the immediate impact of non-caffeinated supplements on energy levels and associated health outcomes

NCT ID: NCT06104852 Recruiting - Alzheimer Disease Clinical Trials

Triage Survey for Neurology Research Eligibility

TRIAGE-Neuro
Start date: June 2, 2023
Phase:
Study type: Observational

TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

NCT ID: NCT06104826 Not yet recruiting - Hemophilia A Clinical Trials

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

ML43518
Start date: December 2023
Phase:
Study type: Observational

The main purposes of this study are to determine if use of emicizumab prophylaxis treatment reduces number of bleeding episodes, if it improves quality of life of individuals and if improves arthropathy in persons with hemophilia A.